LU91882I2 - Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) - Google Patents

Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)

Info

Publication number
LU91882I2
LU91882I2 LU91882C LU91882C LU91882I2 LU 91882 I2 LU91882 I2 LU 91882I2 LU 91882 C LU91882 C LU 91882C LU 91882 C LU91882 C LU 91882C LU 91882 I2 LU91882 I2 LU 91882I2
Authority
LU
Luxembourg
Prior art keywords
veraflox
pradofloxacin
pharmaceutically acceptable
acceptable derivatives
aroma
Prior art date
Application number
LU91882C
Other languages
English (en)
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of LU91882I2 publication Critical patent/LU91882I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LU91882C 2003-11-04 2011-10-12 Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) LU91882I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10351448A DE10351448A1 (de) 2003-11-04 2003-11-04 Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
PCT/EP2004/012327 WO2005044271A1 (fr) 2003-11-04 2004-10-30 Formulations pharmaceutiques aromatisees presentant des proprietes pharmaceutiques ameliorees

Publications (1)

Publication Number Publication Date
LU91882I2 true LU91882I2 (fr) 2013-04-12

Family

ID=34559323

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91882C LU91882I2 (fr) 2003-11-04 2011-10-12 Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)

Country Status (31)

Country Link
US (2) US7858120B2 (fr)
EP (2) EP2080515A1 (fr)
JP (1) JP4892351B2 (fr)
KR (2) KR101325146B1 (fr)
CN (2) CN102335117A (fr)
AR (2) AR046226A1 (fr)
AT (1) ATE454891T1 (fr)
AU (1) AU2004286785B2 (fr)
BR (1) BRPI0416188A (fr)
CA (1) CA2544344C (fr)
CR (1) CR8371A (fr)
CY (2) CY1110541T1 (fr)
DE (2) DE10351448A1 (fr)
DK (1) DK1682144T3 (fr)
ES (1) ES2337793T3 (fr)
HK (1) HK1107008A1 (fr)
HR (1) HRP20100189T1 (fr)
IL (1) IL175147A (fr)
LU (1) LU91882I2 (fr)
MY (1) MY149864A (fr)
NO (1) NO339326B1 (fr)
NZ (1) NZ546921A (fr)
PE (1) PE20050575A1 (fr)
PL (1) PL1682144T3 (fr)
PT (1) PT1682144E (fr)
RU (1) RU2377018C2 (fr)
SI (1) SI1682144T1 (fr)
TW (1) TWI343819B (fr)
UA (1) UA85691C2 (fr)
WO (1) WO2005044271A1 (fr)
ZA (1) ZA200603451B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN100360131C (zh) * 2006-01-24 2008-01-09 新昌国邦化学工业有限公司 一种掩味恩诺沙星的生产方法
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
DE102007004732A1 (de) * 2007-01-31 2008-08-07 Bayer Healthcare Ag Enrofloxacin-Hexahydrat
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US20110223297A1 (en) * 2010-03-12 2011-09-15 Pepsico., Inc. Anti-Caking Agent for Flavored Products
CA2895254C (fr) * 2012-12-19 2021-01-26 Bayer Animal Health Gmbh Comprimes presentant une appetence amelioree et une stabilite au stockage satisfaisante
WO2015042596A1 (fr) * 2013-09-23 2015-03-26 Kindred Biosciences, Inc Traitement de la dermite atopique chez des animaux non humains
TWI749007B (zh) * 2016-04-27 2021-12-11 日商富山化學工業股份有限公司 包含甲苯磺酸托氟沙星之錠劑
TWI727036B (zh) * 2016-04-27 2021-05-11 日商富山化學工業股份有限公司 包含甲苯磺酸托氟沙星、崩解劑及酸性胺基酸之錠劑
CN105997908B (zh) * 2016-06-03 2019-06-21 湖北回盛生物科技有限公司 一种马波沙星牛肉风味片及其制备方法
JP7410050B2 (ja) 2018-04-25 2024-01-09 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング キノロンカルボン酸エステルの加水分解プロセス

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA413698A (fr) * 1943-07-06 Frederick Dauster John Soupape de respiration
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (fr) 1985-09-18 1990-05-05 Pfizer
DE3719764A1 (de) * 1987-06-13 1988-12-22 Bayer Ag Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung
US4910023A (en) 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
US5256699A (en) * 1988-10-18 1993-10-26 Ciba-Geify Corporation Dispersible tablet formulation of diclofenac acid free base
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
WO1994028870A1 (fr) * 1993-06-04 1994-12-22 Warner-Lambert Company Preparations contenant de la silice en ameliorant le gout
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
EP0725037B2 (fr) * 1995-02-04 2012-04-25 Evonik Degussa GmbH Granules à base de silice pyrogène, procédé pour leur préparation et leur utilisation
BR9707606B1 (pt) 1996-02-23 2010-08-10 ácidos 8-ciano-1-ciclopropil-7-(2,8-diazabiciclo(4.3.0) nonan-8-il)-6-flúor-1,4-diidro-4-oxo-3-quinolinocarbo xìlicos, bem como medicamentos que os compreendem.
US20010018417A1 (en) * 1996-07-01 2001-08-30 Carson James W. Virginiamycin mixture
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
CA2216215A1 (fr) * 1997-04-05 1998-10-05 Isa Odidi Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie
US6607754B1 (en) * 1997-07-11 2003-08-19 Upsher-Smith Laboratories, Inc. Delivery of Hypericum perforatum (St. John's Wort) in tablet form
AU741992B2 (en) * 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
HU227070B1 (en) * 1999-08-11 2010-06-28 Egis Gyogyszergyar Nyilvanosan Immediate release pharmaceutical composition containing ciprofloxacin and process for its production
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
AP1485A (en) 2000-03-03 2005-10-31 Ranbaxy Laboratories Ltd Orally administered controlled delivery system for once daily administration of ciprofloxacin.
DE10031044A1 (de) * 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
ES2185452B2 (es) * 2000-08-01 2004-03-16 Cinfa S A Lab Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
EP1247456A3 (fr) * 2001-02-28 2003-12-10 Pfizer Products Inc. Compositions pharmaceutiques savoureux pour les animaux domestiques
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US20030235618A1 (en) * 2001-10-22 2003-12-25 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
WO2003075829A2 (fr) * 2002-03-08 2003-09-18 M/S. Ind-Swift Limited Complexes a dissolution rapide, directement compressibles et insipides et preparations pharmaceutiques a base de ces complexes
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10250711A1 (de) * 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
RS59599B2 (sr) * 2009-11-09 2023-03-31 Wyeth Llc Formulacije tableta neratinib maleata

Also Published As

Publication number Publication date
RU2377018C2 (ru) 2009-12-27
JP4892351B2 (ja) 2012-03-07
ES2337793T3 (es) 2010-04-29
PE20050575A1 (es) 2005-10-27
IL175147A0 (en) 2008-04-13
US20070196466A1 (en) 2007-08-23
UA85691C2 (ru) 2009-02-25
MY149864A (en) 2013-10-31
AU2004286785A8 (en) 2009-08-13
AR046226A1 (es) 2005-11-30
NO20062605L (no) 2006-07-25
TW200517144A (en) 2005-06-01
US7858120B2 (en) 2010-12-28
KR20060109910A (ko) 2006-10-23
NO339326B1 (no) 2016-11-28
DE502004010644D1 (de) 2010-03-04
DK1682144T3 (da) 2010-05-17
RU2006119294A (ru) 2007-12-27
AU2004286785A1 (en) 2005-05-19
EP1682144A1 (fr) 2006-07-26
CY2011017I2 (el) 2016-12-14
ZA200603451B (en) 2007-07-25
CY2011017I1 (el) 2016-12-14
PL1682144T3 (pl) 2010-06-30
KR101325146B1 (ko) 2013-11-07
US20110065719A1 (en) 2011-03-17
CN1972687A (zh) 2007-05-30
BRPI0416188A (pt) 2007-01-23
IL175147A (en) 2014-04-30
SI1682144T1 (sl) 2010-05-31
CA2544344A1 (fr) 2005-05-19
CA2544344C (fr) 2013-10-15
CR8371A (es) 2006-10-10
AU2004286785B2 (en) 2010-08-12
CY1110541T1 (el) 2015-04-29
NZ546921A (en) 2009-08-28
EP2080515A1 (fr) 2009-07-22
ATE454891T1 (de) 2010-01-15
AR108594A2 (es) 2018-09-05
HRP20100189T1 (hr) 2010-05-31
KR20120093299A (ko) 2012-08-22
PT1682144E (pt) 2010-03-09
HK1107008A1 (en) 2008-03-28
TWI343819B (en) 2011-06-21
EP1682144B1 (fr) 2010-01-13
WO2005044271A1 (fr) 2005-05-19
DE10351448A1 (de) 2005-06-09
CN1972687B (zh) 2013-01-23
JP2007510001A (ja) 2007-04-19
CN102335117A (zh) 2012-02-01

Similar Documents

Publication Publication Date Title
LU91882I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
WO2004066910A8 (fr) Complexe modifiant la liberation controlee et compositions pharmaceutiques contenant ledit complexe
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
WO2005065069A3 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
SE9802073D0 (sv) New use
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l'acide et ses sels pour acheminer des agents actifs
NO20070578L (no) Oral doseringsform sikret mot misbruk inneholdende (1,2R)-3-(3-dimetylammino-l-etyl-2-metyl-propyl)-fenol
WO2004073632A3 (fr) Formulations d'agonistes 5-ht selectifs a absorption rapide
MY123149A (en) Solid oral dosage forms of valsartan
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
HUP0500842A2 (hu) Dronedaront tartalmazó gyógyászati készítmény parenterális adagolásra
WO2005044186A3 (fr) Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques